Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2019-10-21 Earnings Release
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from Genomic Vision announcing 'Résultats prometteurs du nouveau test TLA' (Promising results of the new TLA test) resulting from a research collaboration with CMRI. It details scientific findings, quotes management (CEO) and a collaborating professor, and includes standard company/contact information and a forward-looking statement disclaimer. This format is characteristic of an initial announcement of periodic or significant operational/research results, rather than a comprehensive annual report (10-K), a formal interim report (IR), or a transcript (CT). Since it announces key financial/operational highlights (promising research results) immediately, it fits best under the Earnings Release (ER) category, which often encompasses significant operational updates outside of strict quarterly financial reporting, or potentially Regulatory Filings (RNS) if it were purely regulatory. Given the focus on announcing 'results' and updates on a key technology, ER is the most appropriate fit among the specific options, as it serves as an immediate update to the market about performance/progress. FY 2019
2019-10-21 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is an 'Information relative au nombre total de droits de vote et d'actions composant le capital social' (Information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and gross/net voting rights as of a specific date (30.09.2019). This content directly relates to changes in the total number of shares and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the capital structure and voting rights count, SHA is the most precise fit among the defined categories, as it reflects a change or update to the capital base.
2019-10-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 96% confidence The document is a press release announcing a specific business development: the acquisition of Genomic Vision's molecular combing platform by the National Cancer Institute (NCI) for cancer research. It details the technology, quotes the CEO, provides background on both companies (Genomic Vision and NCI), and includes contact information and a forward-looking statement disclaimer. This type of announcement, focusing on a specific operational event, partnership, or technology adoption, does not fit the definitions for standard periodic financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, CAP). It is a general corporate announcement. Since it is not a report announcement (RPA) but the content itself, and it doesn't fit the specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate general category for a significant, non-standard regulatory or business update is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous announcements that are not explicitly defined elsewhere.
2019-09-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release from Genomic Vision announcing that the National Cancer Institute (NCI), part of the NIH, has acquired their molecular combing solution for cancer research. It details the technology's application and includes quotes from the CEO, company background, and contact information. This type of announcement, focusing on a significant business development (a major sale/adoption of technology by a key institution) but not being a formal financial report (like 10-K, IR, or ER), typically falls under general corporate news or regulatory updates. Since it is a specific, positive business announcement that doesn't fit the definitions for ER, CT, CAP, or MANG, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck, but given the press release format, RNS is the most appropriate general category for significant, non-financial-result-specific news, or potentially a specialized announcement if one existed. Given the options, RNS serves as the best fit for a significant, non-standard corporate announcement.
2019-09-25 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document explicitly states it is publishing its "RÉSULTATS SEMESTRIELS 2019" (Half-Year Results 2019) as of June 30, 2019. It contains detailed, unaudited IFRS financial tables covering revenue, operating expenses, and net result for the first half of the year, along with management commentary on performance and financial structure. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. Therefore, the classification is Interim / Quarterly Report (IR). H2 2019
2019-09-24 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document explicitly announces "FIRST-HALF 2019 RESULTS" and provides detailed, unaudited financial tables comparing H1 2019 to H1 2018, including revenue, operating loss, and net loss figures. It discusses key operational highlights for the first half of the year and mentions the next publication date (Q3 2019 revenue). This content structure—a comprehensive financial summary for a period shorter than a year (six months)—is characteristic of an Interim/Quarterly Report. It is not a brief announcement (RPA) because it contains the full financial details, nor is it the Annual Report (10-K). Therefore, the classification is Interim / Quarterly Report (IR). H1 2019
2019-09-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.